Terms: = Prostate cancer AND RAD51B, ENSG00000182185, 5890, RAD51L1, O15315, hREC2, R51H2, REC2, MGC34245
19 results:
1. Genomic characterization of IDH-mutant astrocytoma progression to grade 4 in the treatment setting.
Rautajoki KJ; Jaatinen S; Hartewig A; Tiihonen AM; Annala M; Salonen I; Valkonen M; Simola V; Vuorinen EM; Kivinen A; Rauhala MJ; Nurminen R; Maass KK; Lahtela SL; Jukkola A; Yli-Harja O; Helén P; Pajtler KW; Ruusuvuori P; Haapasalo J; Zhang W; Haapasalo H; Nykter M
Acta Neuropathol Commun; 2023 Nov; 11(1):176. PubMed ID: 37932833
[TBL] [Abstract] [Full Text] [Related]
2. Meta-analysis of
Yu W; Zhao M; Deng Y; Liu S; Du G; Yan B; Zhao Z; Sun N; Guo J
Cancer Imaging; 2023 Aug; 23(1):77. PubMed ID: 37605288
[TBL] [Abstract] [Full Text] [Related]
3. Structure and function of the rad51b-RAD51C-RAD51D-XRCC2 tumour suppressor.
Greenhough LA; Liang CC; Belan O; Kunzelmann S; Maslen S; Rodrigo-Brenni MC; Anand R; Skehel M; Boulton SJ; West SC
Nature; 2023 Jul; 619(7970):650-657. PubMed ID: 37344587
[TBL] [Abstract] [Full Text] [Related]
4. Homologous recombination repair gene mutations in Malaysian prostate cancer patients.
Saeidi H; Raju CS; Ismail P; Raub SHA; Omar N; Hisyam Bakrin I
Cell Mol Biol (Noisy-le-grand); 2022 Aug; 68(8):22-26. PubMed ID: 36800845
[TBL] [Abstract] [Full Text] [Related]
5. A Case Study of Clinical Response to Rucaparib in a Patient with Metastatic Castration-Resistant prostate cancer and a
Sautois B; Loehr A; Watkins SP; Schroeder H; Abida W
Curr Oncol; 2022 Jun; 29(6):4178-4184. PubMed ID: 35735442
[TBL] [Abstract] [Full Text] [Related]
6. Validation of genomic and transcriptomic models of homologous recombination deficiency in a real-world pan-cancer cohort.
Leibowitz BD; Dougherty BV; Bell JSK; Kapilivsky J; Michuda J; Sedgewick AJ; Munson WA; Chandra TA; Dry JR; Beaubier N; Igartua C; Taxter T
BMC Cancer; 2022 May; 22(1):587. PubMed ID: 35643464
[TBL] [Abstract] [Full Text] [Related]
7. Genome-wide analysis of somatic noncoding mutation patterns in cancer.
Dietlein F; Wang AB; Fagre C; Tang A; Besselink NJM; Cuppen E; Li C; Sunyaev SR; Neal JT; Van Allen EM
Science; 2022 Apr; 376(6589):eabg5601. PubMed ID: 35389777
[TBL] [Abstract] [Full Text] [Related]
8. Pain and health-related quality of life with olaparib versus physician's choice of next-generation hormonal drug in patients with metastatic castration-resistant prostate cancer with homologous recombination repair gene alterations (PROfound): an open-label, randomised, phase 3 trial.
Thiery-Vuillemin A; de Bono J; Hussain M; Roubaud G; Procopio G; Shore N; Fizazi K; Dos Anjos G; Gravis G; Joung JY; Matsubara N; Castellano D; Degboe A; Gresty C; Kang J; Allen A; Poehlein C; Saad F
Lancet Oncol; 2022 Mar; 23(3):393-405. PubMed ID: 35157830
[TBL] [Abstract] [Full Text] [Related]
9. Pan-cancer Analysis of Homologous Recombination Repair-associated Gene Alterations and Genome-wide Loss-of-Heterozygosity Score.
Westphalen CB; Fine AD; André F; Ganesan S; Heinemann V; Rouleau E; Turnbull C; Garcia Palacios L; Lopez JA; Sokol ES; Mateo J
Clin Cancer Res; 2022 Apr; 28(7):1412-1421. PubMed ID: 34740923
[TBL] [Abstract] [Full Text] [Related]
10. Honing in on PARPi Response in prostate cancer: from HR Pathway to Gene-by-Gene Granularity.
Sokolova AO; Yu EY; Cheng HH
Clin Cancer Res; 2020 Jun; 26(11):2439-2440. PubMed ID: 32234758
[TBL] [Abstract] [Full Text] [Related]
11. Non-BRCA DNA Damage Repair Gene Alterations and Response to the PARP Inhibitor Rucaparib in Metastatic Castration-Resistant prostate cancer: Analysis From the Phase II TRITON2 Study.
Abida W; Campbell D; Patnaik A; Shapiro JD; Sautois B; Vogelzang NJ; Voog EG; Bryce AH; McDermott R; Ricci F; Rowe J; Zhang J; Piulats JM; Fizazi K; Merseburger AS; Higano CS; Krieger LE; Ryan CJ; Feng FY; Simmons AD; Loehr A; Despain D; Dowson M; Green F; Watkins SP; Golsorkhi T; Chowdhury S
Clin Cancer Res; 2020 Jun; 26(11):2487-2496. PubMed ID: 32086346
[TBL] [Abstract] [Full Text] [Related]
12. Walking Pace Is Associated with Lower Risk of All-Cause and Cause-Specific Mortality.
Celis-Morales CA; Gray S; Petermann F; Iliodromiti S; Welsh P; Lyall DM; Anderson J; Pellicori P; Mackay DF; Pell JP; Sattar N; Gill JMR
Med Sci Sports Exerc; 2019 Mar; 51(3):472-480. PubMed ID: 30303933
[TBL] [Abstract] [Full Text] [Related]
13. Simple risk assessment in prostate cancer patients treated with primary androgen deprivation therapy: The Korean cancer Study of the prostate risk classification.
Choi SY; Ryu J; You D; Hong JH; Ahn H; Kim CS
Int J Urol; 2019 Jan; 26(1):62-68. PubMed ID: 30238513
[TBL] [Abstract] [Full Text] [Related]
14. Gene and pathway level analyses of germline DNA-repair gene variants and prostate cancer susceptibility using the iCOGS-genotyping array.
Saunders EJ; Dadaev T; Leongamornlert DA; Al Olama AA; Benlloch S; Giles GG; Wiklund F; Gronberg H; Haiman CA; Schleutker J; Nordestgaard BG; Travis RC; Neal D; Pasayan N; Khaw KT; Stanford JL; Blot WJ; Thibodeau SN; Maier C; Kibel AS; Cybulski C; Cannon-Albright L; Brenner H; Park JY; Kaneva R; Batra J; Teixeira MR; Pandha H; Govindasami K; Muir K; ; ; ; Easton DF; Eeles RA; Kote-Jarai Z
Br J Cancer; 2016 Apr; 114(8):945-52. PubMed ID: 26964030
[TBL] [Abstract] [Full Text] [Related]
15. A Cross-cancer Genetic Association Analysis of the DNA Repair and DNA Damage Signaling Pathways for Lung, Ovary, prostate, Breast, and Colorectal cancer.
Scarbrough PM; Weber RP; Iversen ES; Brhane Y; Amos CI; Kraft P; Hung RJ; Sellers TA; Witte JS; Pharoah P; Henderson BE; Gruber SB; Hunter DJ; Garber JE; Joshi AD; McDonnell K; Easton DF; Eeles R; Kote-Jarai Z; Muir K; Doherty JA; Schildkraut JM
Cancer Epidemiol Biomarkers Prev; 2016 Jan; 25(1):193-200. PubMed ID: 26637267
[TBL] [Abstract] [Full Text] [Related]
16. Polymorphisms of homologous recombination RAD51, rad51b, XRCC2, and XRCC3 genes and the risk of prostate cancer.
Nowacka-Zawisza M; Wiśnik E; Wasilewski A; Skowrońska M; Forma E; Bryś M; Różański W; Krajewska WM
Anal Cell Pathol (Amst); 2015; 2015():828646. PubMed ID: 26339569
[TBL] [Abstract] [Full Text] [Related]
17. Additive interactions between susceptibility single-nucleotide polymorphisms identified in genome-wide association studies and breast cancer risk factors in the Breast and prostate cancer Cohort Consortium.
Joshi AD; Lindström S; Hüsing A; Barrdahl M; VanderWeele TJ; Campa D; Canzian F; Gaudet MM; Figueroa JD; Baglietto L; Berg CD; Buring JE; Chanock SJ; Chirlaque MD; Diver WR; Dossus L; Giles GG; Haiman CA; Hankinson SE; Henderson BE; Hoover RN; Hunter DJ; Isaacs C; Kaaks R; Kolonel LN; Krogh V; Le Marchand L; Lee IM; Lund E; McCarty CA; Overvad K; Peeters PH; Riboli E; Schumacher F; Severi G; Stram DO; Sund M; Thun MJ; Travis RC; Trichopoulos D; Willett WC; Zhang S; Ziegler RG; Kraft P;
Am J Epidemiol; 2014 Nov; 180(10):1018-27. PubMed ID: 25255808
[TBL] [Abstract] [Full Text] [Related]
18. Interactions between genetic variants and breast cancer risk factors in the breast and prostate cancer cohort consortium.
Campa D; Kaaks R; Le Marchand L; Haiman CA; Travis RC; Berg CD; Buring JE; Chanock SJ; Diver WR; Dostal L; Fournier A; Hankinson SE; Henderson BE; Hoover RN; Isaacs C; Johansson M; Kolonel LN; Kraft P; Lee IM; McCarty CA; Overvad K; Panico S; Peeters PH; Riboli E; Sanchez MJ; Schumacher FR; Skeie G; Stram DO; Thun MJ; Trichopoulos D; Zhang S; Ziegler RG; Hunter DJ; Lindström S; Canzian F
J Natl Cancer Inst; 2011 Aug; 103(16):1252-63. PubMed ID: 21791674
[TBL] [Abstract] [Full Text] [Related]
19. Isolation of human and mouse genes based on homology to rec2, a recombinational repair gene from the fungus Ustilago maydis.
Rice MC; Smith ST; Bullrich F; Havre P; Kmiec EB
Proc Natl Acad Sci U S A; 1997 Jul; 94(14):7417-22. PubMed ID: 9207106
[TBL] [Abstract] [Full Text] [Related]
